EyePoint (EYPT) Cash from Investing Activities (2010 - 2026)

EyePoint (EYPT) reported Cash from Investing Activities of $59.1 million for Q1 2026, up 49.41% on a YoY basis from $39.5 million in Q1 2025, and up 179.09% sequentially from -$74.7 million in Q4 2025.

EyePoint (EYPT) Cash from Investing Activities (2010 - 2026) Analysis & Trends

EyePoint (EYPT) has 17 years of Cash from Investing Activities data on file, last reported at $59.1 million in Q1 2026.

  • For the quarter ending Q1 2026, Cash from Investing Activities rose 49.41% year-over-year to $59.1 million; the trailing twelve-month figure through Mar 2026 stood at $88.1 million (up 143.91% YoY), and the FY2025 full-year result was $68.6 million, up 131.26% from the prior year.
  • Cash from Investing Activities climbed to $59.1 million in Q1 2026, from -$74.7 million in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $59.1 million in Q1 2026 to a low of -$160.4 million in Q2 2024.
  • A 5-year average of -$6.6 million and a median of $13.5 million in 2023 frame the typical range for Cash from Investing Activities.
  • Across the five-year window, Cash from Investing Activities jumped 112325.0% in 2023 and sank 1291.02% in 2024, its largest moves.
  • Tracing EYPT's Cash from Investing Activities over 5 years: stood at $32.9 million in 2022, then sank by 243.23% to -$47.1 million in 2023, then plunged by 103.53% to -$96.0 million in 2024, then gained by 22.19% to -$74.7 million in 2025, then jumped by 179.09% to $59.1 million in 2026.
  • Business Quant data shows EYPT's Cash from Investing Activities at $59.1 million in Q1 2026, -$74.7 million in Q4 2025, and $55.4 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Investing Activities (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn -45.51 Mn
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn -431.90 Mn
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn -428.90 Mn
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn -
9 Revolution Medicines 37.35 Bn 37.35 Bn - 172.62 Mn
10 EyePoint 1.07 Mn -221.48 Mn 168,000.00 59.05 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 59.05 Mn
Mar 31, 2026 59.05 Mn
Dec 31, 2025 -74.67 Mn
Dec 31, 2025 -74.67 Mn
Sep 30, 2025 55.39 Mn
Sep 30, 2025 55.39 Mn
Jun 30, 2025 48.34 Mn
Jun 30, 2025 48.34 Mn
Mar 31, 2025 39.53 Mn
Mar 31, 2025 39.53 Mn
Dec 31, 2024 -95.96 Mn
Dec 31, 2024 -95.96 Mn
Sep 30, 2024 16.20 Mn
Sep 30, 2024 16.20 Mn
Jun 30, 2024 -160.40 Mn
Jun 30, 2024 -160.40 Mn
Mar 31, 2024 20.81 Mn
Mar 31, 2024 20.81 Mn
Dec 31, 2023 -47.15 Mn
Dec 31, 2023 -47.15 Mn